Journals / Acta Medica Alanya / 2026 / Cilt: 10 Sayı: 2

Multiple Sclerosis in Childhood: Report of 24 Cases from a Single-Center Experience

Çocukluk Çağı Multipl Sklerozu: Tek Merkez Deneyiminden 24 Olgunun Değerlendirilmesi

Sait Açık(AKDENIZ UNIVERSITY)0000-0002-1177-8438
Şakir Genç(Sağlık Bilimleri Üniversitesi Antalya Eğitim ve Araştırma Hastanesi)0000-0002-7042-8307
Pages
103–111
Publication Date
2026-08-16
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Real-world data from single-center cohorts remain valuable for refining therapeutic strategies and improving outcomes in pediatric MS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To examine the clinical, radiological, and therapeutic characteristics of pediatric patients with multiple sclerosis (MS) at a single tertiary center.
📊
Key Findings & Data:Methods: This retrospective study included 24 patients diagnosed with MS according to the 2017 revised McDonald criteria.
💡
Conclusion & Impact:Real-world data from single-center cohorts remain valuable for refining therapeutic strategies and improving outcomes in pediatric MS.
🔬Design:Araştırma Makalesi
📍Scope:2017 Verileri
⚙️Variables:Pediatrik multipl skleroz · Demiyelinizan hastalıklar · Hastalık modifiye edici tedavi

Abstract

Aim: To examine the clinical, radiological, and therapeutic characteristics of pediatric patients with multiple sclerosis (MS) at a single tertiary center. Methods: This retrospective study included 24 patients diagnosed with MS according to the 2017 revised McDonald criteria. The demographic, clinical, neurophysiological, and magnetic resonance imaging (MRI) data, as well as treatment responses and long-term outcomes, were analyzed. Results: The mean age at first clinical attack was 13.7 ± 3.4 years (range: 5.4–17.9), and the mean age at diagnosis was 13.8 ± 3.4 years (range: 5.8–18.2). The mean follow-up duration was 53.6 ± 27 months. At diagnosis, 52.2% of the patients were monosymptomatic, and sensory symptoms were most common. MRI revealed periventricular and infratentorial lesions in 54.5% of the cases each. While 31.8% of the patients remained on first-line disease-modifying therapies (DMTs), 68.2% required escalation to second-line and 18.2% to third-line treatments. A shorter duration of first-line DMT (median 6 months, p<0.05) was associated with the need for third-line therapy. Permanent neurological sequelae developed in 34.8% of the patients. Conclusion: Pediatric MS may exhibit high early disease activity and require rapid treatment escalation. Early identification of suboptimal treatment response is crucial to prevent long-term disability. Real-world data from single-center cohorts remain valuable for refining therapeutic strategies and improving outcomes in pediatric MS.

Özet

Amaç: Bu çalışma, tek bir üçüncü basamak merkezde izlenen çocukluk çağı multipl skleroz olgularının klinik, radyolojik ve tedaviye ilişkin özelliklerini tanımlamayı amaçlamıştır. Yöntem: 2017 revize McDonald kriterlerine göre multipl skleroz tanısı konulan 24 hasta retrospektif olarak değerlendirildi. Demografik, klinik, nörofizyolojik, manyetik rezonans görüntüleme (MRG) verileri ve tedavi yanıtları incelendi. Bulgular: İlk klinik atak yaşı ortalama 13.7 ± 3.4 yıl (aralık: 5.4–17.9), tanı yaşı ortalama 13.8 ± 3.4 yıl (aralık: 5.8–18.2) ve ortalama izlem süresi 53,6 ± 27 aydı. Tanı anında hastaların %52,2’si monosemptomatikti ve en sık duyu semptomlarıyla başvurdu. MRG’de en yaygın lezyon bölgeleri periventriküler ve infratentoryal alanlardı (her biri %54,5). Hastaların %31.8’i birinci basamak hastalık modifiye edici tedavilere (HMT) yanıt verirken, %68.2’i ikinci basamak ve %18.2’sı üçüncü basamak tedaviye ihtiyaç duydu. Birinci basamak HMT süresi kısa olan olgularda üçüncü basamak tedavi gereksinimi anlamlı olarak daha yüksekti (median 6 ay, p < 0.05). Kalıcı nörolojik sekel oranı %34,8 idi. Sonuç: Çocukluk çağı multipl sklerozu yüksek erken hastalık aktivitesi gösterebilir ve hızlı tedavi basamak değişimi gerektirebilir. Erken dönemde yetersiz tedavi yanıtının saptanması, uzun dönem dizabiliteyi önlemede kritik öneme sahiptir. Tek merkezli gerçek yaşam verileri, tedavi stratejilerinin geliştirilmesine ve pediatrik multipl skleroz prognozunun iyileştirilmesine katkı sağlayabilir.

🔖

Cite This Article

Tsakir, C., Saçın, S. Ö., Donbaloğlu, F., Yanartaş, M. S., Açık, S., Genç, Ş., Köken, Ö. Y., Haspolat, Ş. (2026). Multiple Sclerosis in Childhood: Report of 24 Cases from a Single-Center Experience. Acta Medica Alanya, Cilt: 10 Sayı: 2, 103–111. https://doi.org/10.30565/medalanya.1807609

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19(10):1261–7. doi: 10.1177/1352458513484547.
  2. Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012;18(1):116–27. doi: 10.1177/1352458511430704.
  3. Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol. 2007;6(10):887–902. doi: 10.1016/S1474-4422(07)70242-9.
  4. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73. doi: 10.1016/S1474-4422(17)30470-2.
  5. Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, et al. Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol. 2019;6(9):1905–22. doi: 10.1002/acn3.50862.
  6. Bulut MN, Oral AY, Bulut K. Pattern VEP (Visually Evoked Potentials) Normal Values. J Kartal TR 2015;26(2):109–114. doi: 10.5505/jkartaltr.2015.82957.
  7. Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J. Natalizumab Use in Pediatric Multiple Sclerosis. Arch Neurol. 2008;65(12):1655-8. doi: 10.1001/archneur.65.12.1655.
  8. Yamout B, Al-Jumah M, Sahraian MA, Almalik Y, Khaburi J Al, Shalaby N, et al. Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines. Mult Scler Relat Disord. 2024;83:105435. doi: 10.1016/j.msard.2024.105435.
  9. Oertel FC, Krämer J, Motamedi S, Keihani A, Zimmermann HG, Dimitriou NG, et al. Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort. Neurol Neuroimmunol Neuroinflamm. 2023;10(3):e200092. doi: 10.1212/NXI.0000000000200092.
  10. Soker EB, Erdem M, Ozdogru D, Gencler OS, Yesiloglu O, Fidanci H. The potential of visual evoked potentials latency and amplitude to be a subclinical predictor of clinical prognosis in multiple sclerosis. Ir J Med Sci. 2025;194(4):1409-15. doi: 10.1007/s11845-025-03980-x.
  11. Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018;18(1):27. doi: 10.1186/s12883-018-1026-3.
  12. Yılmaz Ü, Anlar B, Gücüyener K, Yaramış A, Cansu A, Ünalp A, et al. Characteristics of pediatric multiple sclerosis: The Turkish pediatric multiple sclerosis database. Eur J Paediatr Neurol. 2017;21(6):864-72. doi: 10.1016/j.ejpn.2017.06.004.
  13. Waldman A, Ness J, Pohl D, Simone IL, Anlar B, Amato MP, et al. Pediatric multiple sclerosis. Neurology. 2016;87(9 Suppl 2):S74-81. doi: 10.1212/WNL.0000000000003028.
  14. Sadaka Y, Verhey LH, Shroff MM, Branson HM, Arnold DL, Narayanan S, et al. 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol. 2012;72(2):211–23. doi: 10.1002/ana.23575.
  15. Nikolic B, Zaletel I, Ivancevic N, Rovcanin B, Pepic A, Samardzic J, et al. The usefulness of visual evoked potentials in the assessment of the pediatric multiple sclerosis. Eur J Paediatr Neurol. 2022;36:130-6. doi: 10.1016/j.ejpn.2021.12.005.
  16. Abdel‐Mannan O, Absoud M, Benetou C, Hickson H, Hemingway C, Lim M, et al. Incidence of paediatric multiple sclerosis and other acquired demyelinating syndromes: 10‐year follow‐up surveillance study. Dev Med Child Neurol. 2022;64(4):502–8. doi: 10.1111/dmcn.15098.
  17. Öztürk Z, Gücüyener K, Soysal Ş, Konuşkan GD, Konuşkan B, Dikmen AU, et al. Cognitive functions in pediatric multiple sclerosis: 2-years follow-up. Neurol Res. 2020;42(2):159–63. doi: 10.1080/01616412.2019.1710417.
  18. Brola W, Steinborn B. Pediatric multiple sclerosis – current status of epidemiology, diagnosis and treatment. Neurol Neurochir Pol. 2020;54(6):508–17. doi: 10.5603/PJNNS.a2020.0069.
  19. Lips P, Cashman KD, Lamberg-Allardt C, Bischoff-Ferrari HA, Obermayer-Pietsch B, Bianchi ML, et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. Eur J Endocrinol. 2019;180(4):P23–54. doi: 10.1530/EJE-18-0736.
  20. Yılmaz Ü, Anlar B, Gücüyener K, Yaramış A, Cansu A, Ünalp A, et al. Characteristics of pediatric multiple sclerosis: The Turkish pediatric multiple sclerosis database. Eur J Paediatr Neurol. 2017;21(6):864-72. doi: 10.1016/j.ejpn.2017.06.004.